GlobeNewswire by notified

Bestyrelsens beslutning om udstedelse af et konvertibelt lån

Del

BRØNDBYERNES I.F. FODBOLD A/S CVR-nr. 83 93 34 10

Brøndby, den 24. november 2022 SELSKABSMEDDELELSE NR. 18/2022

Bestyrelsens beslutning om udstedelse af et konvertibelt lån

Bestyrelsen i Brøndby IF fik på den ekstraordinære generalforsamling den 22. november 2022 en bemyndigelse, jf. § 3c i selskabets vedtægter, til at udstede konvertible lån.

Bestyrelsen har i dag truffet beslutning om udstedelse af et konvertibelt lån til Global Football Holdings, L.P og Jan Flemming Bech Andersen i henhold til den af generalforsamlingen meddelte bemyndigelse i § 3c i selskabets vedtægter. Det konvertible lån giver Brøndby IF mulighed for at låne op til 223.179.000 kr. Vilkårene er blandt andet som følger:

  • At det konvertible lån forrentes med 5% p.a., og at lånet løber i 8 år fra datoen for indgåelse af det konvertible lån,
  • at det konvertible lån kan konverteres til aktier med en nominel værdi på 0,25 kr., og at tegningskursen ved konvertering er kurs 220 svarende til en pris per aktie på 0,55 kr.,
  • at der ved udnyttelse af det konvertible lån ved konvertering af lånet til aktier oprettes to kapitalklasser, og at de nye aktier skal tilhøre en nyoprettet aktieklasse B, idet disse B-aktier skal have samme rettigheder som selskabets eksisterende aktier, der bliver A-aktier, bortset fra at B-aktierne skal være unoterede, hvor A-aktierne fortsat skal vedblive med at være noterede,
  • at der maksimalt kan ske forhøjelse af selskabskapitalen med 160.000.000 kr.,
  • at tegningsfristen for det konvertible lån er op til 6 uger.

De resterende vilkår for det konvertible lån vil blive fastlagt i en konvertibel låneaftale, og vilkår for konvertering af lån til aktier vil blive indarbejdet i selskabets vedtægter samt et vedtægtsbilag. Selskabets vedtægter og vedtægtsbilaget vil blive lagt på hjemmesiden, såfremt den konvertible gæld bliver tegnet.

Bestyrelsen vil orientere markedet om resultatet af tegningen af den konvertible gæld.

Information
Yderligere information om denne meddelelse kan fås hos kommunikationschef Christian Schultz på telefon 31 41 41 85.

Vedhæftet fil

For at se dette indhold fra www.globenewswire.com, så skal du give din accept på toppen af denne side.
For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.

Information om GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg pressemeddelelser fra GlobeNewswire by notified

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra GlobeNewswire by notified

Major shareholder notification – Norges Bank3.12.2022 14:45:28 CET | Press release

GN Store Nord A/S hereby announces that on December 2, 2022, pursuant to Section 38(1) and Section 39(1) of the Danish Capital Markets Act, it received a notification from Norges Bank stating that on December 1, 2022 Norges Bank decreased its aggregate holding of shares and financial instruments, cf. Section 38(1) and Section 39(2)(1) of the Danish Capital Markets Act, to under 5% of the share capital and voting rights in GN Store Nord A/S. For further information, please contact: Investors and analysts Anne Sofie Staunsbæk Veyhe Vice President – Investor Relations, Treasury & M&A Tel: +45 45 75 85 06 or Rune Sandager Senior Director – Investor Relations Tel: +45 45 75 92 57 Press and the media Steen Frentz Laursen Vice President, Corporate Communications Tel: +45 20 65 34 20 About GN GN facilitates communication between people through intelligent hearing, audio, video, and gaming technology. Inspired by people and driven by our passion for innovation, we leverage technologies to deliv

Brookfield Announces Reset Dividend Rate on Its Series 30 and Series 48 Preference Shares3.12.2022 03:45:00 CET | Press release

All amounts in Canadian dollars unless otherwise stated. BROOKFIELD, NEWS, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Brookfield (NYSE: BAM, TSX: BAM.A) today announced that it has determined the fixed dividend rate on its Cumulative Class A Preference Shares, Series 30 (“Series 30 Shares”) (TSX: BAM.PR.Z) for the five years commencing January 1, 2023 and ending December 31, 2027, and also determined the fixed dividend on its Cumulative Class A Preference Shares, Series 48 (“Series 48 Shares”) (TSX: BAM.PF.J) for the five years commencing January 1, 2023 and ending December 31, 2027. As previously disclosed, the Series 30 Shares and Series 48 Shares are expected to commence trading on the TSX under the updated symbols “BN.PR.Z” and “BN.PF.J”, respectively, on December 12, 2022. Series 30 Shares and Series 31 Shares If declared, the fixed quarterly dividends on the Series 30 Shares during the five years commencing January 1, 2023 will be paid at an annual rate of 6.089% ($0.3805625 per share per

EverWind selects Black & Veatch for Front-end Engineering Design of First Green Hydrogen Hub in Nova Scotia2.12.2022 20:23:30 CET | Press release

HALIFAX, Nova Scotia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- EverWind Fuels Company ("EverWind") today announces it has selected Black & Veatch to provide front-end engineering design (FEED) services for its green hydrogen and ammonia production and storage facility in Point Tupper, Nova Scotia, with initial commercial operations planned for 2025. EverWind is a private developer of green hydrogen and ammonia production and storage sites, and global engineering and construction company Black & Veatch is a green energy solutions leader. In its first phase, the facility will produce green hydrogen and green ammonia through electrolysis using certified green power from the Nova Scotia Power transmission system; onshore wind generation will power production in a second phase. In future phases, EverWind will use offshore wind power to produce hydrogen through electrolysis, unlocking Nova Scotia’s offshore wind capabilities. The first two phases will produce a combined 1 million tonnes per annum o

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA2.12.2022 19:00:00 CET | Press release

Negma Group has converted 322convertible bonds in Oxurion resulting in a EUR 805,000capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5billion. Leuven, BELGIUM,Boston, MA, US–December2, 2022– 07.00 PM CET – In accordance with article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), announces the below information, following (i) the issuance of 63,550,419 new ordinary shares on November 28, 2022, for a total amount of EUR 605,000, as the result of the conversion of 242 class B convertible bonds, and (ii) the issuance of 21,008,403 new ordinary shares on November 30, 2022, for a total amount

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons2.12.2022 18:05:00 CET | Press release

Company announcement – No. 56/ 2022 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark and Boston, MA, U.S. December 2, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions. Please see the attached file(s). # # # About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have re